Astrana Health (NASDAQ:ASTH) jumps 9.7% this week, though earnings growth is still tracking behind five-year shareholder returns

Simply Wall St · 10/17 16:19

Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock performs well, when investors win, they can win big. Just think about the savvy investors who held Astrana Health, Inc. (NASDAQ:ASTH) shares for the last five years, while they gained 330%. If that doesn't get you thinking about long term investing, we don't know what will. On top of that, the share price is up 27% in about a quarter.

The past week has proven to be lucrative for Astrana Health investors, so let's see if fundamentals drove the company's five-year performance.

See our latest analysis for Astrana Health

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Over half a decade, Astrana Health managed to grow its earnings per share at 37% a year. This EPS growth is reasonably close to the 34% average annual increase in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. In fact, the share price seems to largely reflect the EPS growth.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

earnings-per-share-growth
NasdaqCM:ASTH Earnings Per Share Growth October 17th 2024

We know that Astrana Health has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.

A Different Perspective

It's nice to see that Astrana Health shareholders have received a total shareholder return of 97% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 34% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Astrana Health .

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.